NR1H4 and gallstones: DCA, as an FXR agonist (Wahlstrom et al., 2016), increases human gallbladder cholesterol saturation and bile acid hydrophobicity, and both decrease cholesterol solubility in bile and increase the risk of gallstone formation (Heaton, 2000).